Parnell Pharmaceuticals Holdings Gross Profit 2014-2018 | PARNF
Parnell Pharmaceuticals Holdings gross profit from 2014 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Parnell Pharmaceuticals Holdings Annual Gross Profit
(Millions of US $) |
| 2021 |
$16 |
| 2020 |
$9 |
| 2019 |
$12 |
| 2018 |
$15 |
| 2017 |
$9 |
| 2016 |
$8 |
| 2015 |
$9 |
| 2014 |
$8 |
| 2014 |
$0 |
| 2013 |
$3 |
| 2013 |
$0 |
| 2012 |
$4 |
Parnell Pharmaceuticals Holdings Quarterly Gross Profit
(Millions of US $) |
| 2018-06-30 |
|
| 2018-03-31 |
$3 |
| 2017-12-31 |
|
| 2016-12-31 |
$4 |
| 2016-09-30 |
$4 |
| 2015-12-31 |
$3 |
| 2015-09-30 |
$3 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
|
| 2014-03-31 |
$1 |
| 2013-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
